Demand comes among antitrust agency’s recent denial of Amgen’s Horizon buyout.
The Federal Trade Commission (FTC) has asked for more information on Pfizer’s proposed $43 billion takeover of Seagan, a biotechnology company. The request, which comes after the agency’s shutdown of Amgen’s attempt to purchase Horizon Therapeutics for $27.8 billion, has made investors skittish at the potential outcome.
Despite the request, Seagan continues to expect its merger with Pfizer will be completed in late 2023 or early 2024.
Reference: US FTC Seeks Additional Info on Pfizer's Proposed Takeover of Seagen. Reuters. July 14, 2023. Accessed July 17, 2023. https://www.reuters.com/markets/deals/us-ftc-seeks-additional-info-pfizers-proposed-takeover-seagen-2023-07-14/
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.